The immune checkpoint inhibitor avelumab was approved as first-line maintenance treatment for patients with advanced urothelial carcinoma (UC) that has not progressed on first-line platinum-containing chemotherapy. The approval was based on data from the phase 3 JAVELIN Bladder 100 trial. Avelumab first-line maintenance is now considered the standard-of-care treatment for this patient group.
Infusion nurses are at the front line of patient care and play a vital role throughout the treatment journey of patients with advanced UC.
In this video, based on the publication ‘Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses’, Dawn Conway (University of Chicago Medicine, IL, USA) reviews key considerations related to avelumab first-line maintenance therapy that infusion nurses should be familiar with. These include dosing, administration, and immune-related adverse event recognition and management, to ensure safe and appropriate use of this important and impactful therapy.
Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses.
Laura S Wood, Dawn Conway, Maria Lapuente, George Salvador, Sheila Fernandez Gomez, Andrea Carroll Bullock, Geeta Devgan & Kathleen D Burns.
Journal of Infusion Nursing (2022) doi.org/10.1097/NAN.0000000000000465
Meet the speaker:
Dawn Conway has been an oncology nurse for 15 years, starting her career as a bone marrow transplant nurse at Mount Sinai Hospital in New York City. After three years, she moved back to Chicago and started her role as a Nurse Navigator in the GU oncology program at the University of Chicago Medicine. For the past 12 years Dawn has primarily worked with patients diagnosed with metastatic urothelial cancer and has become an expert in the management of this patient population.